CM-EV increased TGF-β1 production and miR-155-5p and miR-142-3p expression, resulting in increased survival, decreased anti-dsDNA antibody levels, and improved renal histopathology in a mouse model of SLE. This evidence concerns the gene TGFB1 and systemic lupus erythematosus.